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Anti-EGFRAbstract Head and neck squamous cell carcinoma (HNSCC) accounts for a large oncologic
burden in the developing countries. In patients with locally advanced head and neck cancer
multimodality treatment is warranted. Radiation therapy with concurrent chemotherapy has long
been considered the standard for patients with disease involving the oropharynx, larynx and
hypopharynx. However, addition of chemotherapy to radiotherapy increases treatment related tox-
icity by many folds and compliance rates decrease. In this context a systemic therapy, which when
used concurrent with radiation with favorable toxicity proﬁle is of great importance for improving
disease control in locally advanced HNSCC. Anti-epithelial growth factor receptor targeted therapy
emerged as a potential treatment option. In recent years many trials were conducted to ﬁnd the opti-
mum treatment option with the combination of these targeted agents. The initial trials showed
excellent results with minimal morbidity and led to great enthusiasm across the globe to incorporate
these regimens as a standard of care. However, subsequently many trials failed to maintain such
results and now there is little agreement to the initial results achieved with these drugs. Based on
the current evidence we cannot recommend the replacement of cisplatin with targeted therapy in
concurrent setting. It may be considered in patients with altered renal parameters, hypersensitivity
or intolerance to cisplatin. The addition of targeted therapy in addition to chemotherapy in the
concurrent setting can’t also be recommended as the beneﬁt is doubtful and is associated with a
signiﬁcant increase in toxicity.
 2016 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Head and neck squamous cell carcinoma (HNSCC) accounts
for large oncologic burden in the developing countries [1]. A
large majority of these patients present in locally advanced
stage and require a multimodality therapy [2]. The treatment
option varies from radio-chemotherapy, surgery followed by
radiotherapy, induction chemotherapy followed by radio-
chemotherapy, altered fractionation radiotherapy. The best
outcome in inoperable oral cavity lesions and other locally
advanced head and neck cancers has been with concurrent
chemoradiation [3]. However, treatment related toxicity is
often the limiting factor and may lead to radiotherapy treat-
ment breaks and leads to survival detriment [4]. In addition
end organ compromise and co-morbidity makes it challenging
to treat such patient to the optimum. Epithelial growth factor
receptor (EGFR) is found in about 80% of the patients of
head and neck squamous cell carcinoma [5]. The research for
alternate agents, have paved way for less toxic, equally effec-
tive targeted therapy. Cetuximab was the ﬁrst drug to be
shown to be effective in the concurrent setting in radically trea-
ted head and neck patients. The survival beneﬁt by addition of
Cetuximab to radiotherapy was in fact higher than that from
concurrent chemotherapy reported from the meta-analysis.
Trials further evaluated other agents like Panitumumab, other
agents also in the concurrent setting. The good results in con-
current setting also led to trials evaluating the addition of tar-
geted therapy along with chemotherapy and radiotherapy. We
here intend to systematically review these trials in which tar-
geted therapy has been used in a radical setting in head and
neck squamous cell carcinoma.
Targeted therapy with radiotherapy
Radiotherapy with concurrent cisplatin was found to be the
best therapeutic approach with 6.5% overall survival beneﬁt
at 5 years [6]. The results of the meta-analysis revealed the ben-
eﬁt of concurrent chemotherapy (CTRT) in all head and neck
sub-sites. However, acute and late toxicity are the major limi-
tation and compliance was a major issue. The HNSCC
patients are often elderly and not suitable for chemotherapy
because of end organ damage and multiple co-morbidities.
This led researchers to ﬁnd an alternate drug with similar efﬁ-
cacy but lesser toxicity and thus better tolerance among these
patients. Epithelial growth factor receptor (EGFR) being overexpressed in about 80% of the patients of head and neck squa-
mous cell carcinoma was an excellent target. The initial phase I
trial reported the addition of Cetuximab with radiotherapy in
locally advanced head and neck cancer is well tolerated [7].
This led Bonner et al. to conduct a phase III randomized
trial to see the survival beneﬁt of addition of Cetuximab to
radical radiotherapy. Bonner et al. in this land mark phase
III trial, randomized 424 patients to receive radical radiation
plus concurrent Cetuximab (400 mg/m2 loading dose followed
by 250 mg/m2 weekly) versus radical radiation alone [8].
Cetuximab was found to signiﬁcantly improve loco-regional
progression-free survival (median 24.4 vs. 14.9 months) and
overall survival (median 49 vs. 29.3 months) compared to radi-
ation alone. The 5 year updated results showed an absolute
5 year beneﬁt of 9.2% with addition of Cetuximab. 17%
patients developed grade 3 or higher acneiform rash. It was
also noted that patients who had a grade II or higher skin rash
had signiﬁcantly better survival than those with no or grade I
rash.
The better survival beneﬁt shown by Bonner trial must also
be seen with the fact that 90% of the patients in Bonner trial
could complete the scheduled treatment while the scheduled
chemo radiation is generally possible in only 50% of the
patients. The toxicity proﬁle in patients in the Bonner trial
was also encouraging as well as there were a few treatment
interruptions in the Cetuximab arm when compared to those
in historical radio chemotherapy patients. But, as of now,
there is no randomized phase III trial comparing concurrent
cisplatin vs. Cetuximab head on. Though, the survival beneﬁt
with concurrent Cetuximab appears higher than cisplatin [9.2
vs. 6.5] note must also be kept that the data regarding
Cetuximab is based on a trial of 425 patients while the data
on cisplatin is based on meta-analysis of more than 17,000
patients. When interpreting the results of the Bonner trial it
must be also noted that the radiotherapy was not uniform,
one group received conventional fractionation while there were
groups with hyper fractionation and one group receiving
concomitant boost.
There are also a few retrospective reviews that have
addressed this issue. Lawrence Koutcher in a retrospective
review of 174 patients aimed to compare concurrent cisplatin
vs. Cetuximab in locally advanced head and neck cancers [9].
The results showed 2 year overall survival of 87.4% and
44.5% for the cisplatin and Cetuximab arm respectively. The
survival difference that was proven in univariate analysis
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results of this study must be taken with a pinch of salt because
of its retrospective nature and possible difference in selection
bias between the two groups. It must be noted that the
reported two year survival in the Cetuximab arm is even less
than that in the standard radiotherapy alone arm further
increasing the suspicion of selection bias.
Petrelli et al. did a systematic review and meta-analysis to
compare concomitant platinum based chemotherapy vs.
Cetuximab with radiotherapy for locally advanced head and
neck cancer [10]. The analysis included ﬁfteen trials, including
a total of 1808 patients. It was concluded that concomitant
radio chemotherapy signiﬁcantly improved 2-year overall
survival (p= 0.02) and 2-year progression free survival
(p= 0.002) when compared to Cetuximab with radiotherapy.
But the meta-analysis can’t be considered as conclusive
evidence as there are no phase III trials comparing head to
head CTRT and bioradiotherapy (BioRT) and the retrospec-
tive trials may be biased toward recruiting patients in poor
general condition to BioRT.
Other agents have also been tried in the concurrent setting.
Giralt et al. in a phase II trial [CONSERT II] evaluated
Panitumumab plus radiotherapy versus radio chemotherapy
in patients with locally advanced squamous-cell carcinoma of
the head and neck [11]. Progression-free survival events
occurred in 39% of patients in the radio chemotherapy group
and 59% of patients in the radiotherapy plus Panitumumab
group (p= 0.03). Overall survival at 2 years in patients receiv-
ing radio chemotherapy was 71% vs. 63% in patients receiving
radiotherapy plus Panitumumab.
Rodriguez et al. evaluated the role of Nimotuzumab with
radiotherapy for unresectable squamous-cell carcinoma of
the head and neck [12]. This double blind, randomized clinical
trial included 106 patients of advanced squamous cell carci-
noma of the head and neck. Analysis of data revealed median
survival of the patients treated with Nimotuzumab and radio-
therapy (RT) of 12.50 months while 9.47 months for placebo
plus irradiation.
Hence based on available data we cannot recommend bio
radiotherapy over chemo radiotherapy in locally advanced car-
cinoma of head and neck in the absence of deﬁnite evidence of
superiority. But it can be used as a feasible option in patients
whomay not tolerate cisplatin due to age or those with impaired
renal function. Also it may be considered in patients with poor
performance status and patients with allergy to cisplatin.Targeted therapy with radical radio-chemotherapy
Survival beneﬁt and favorable toxicity proﬁle of Cetuximab in
the concurrent setting encouraged to start the RTOG 0522
trial which compared accelerated radiation plus concurrent cis-
platin with or without Cetuximab for stage III and IV head
and neck carcinoma [13]. The clinical rationale for this study
was that Cetuximab enhances tumor response when added to
cisplatin and radiotherapy thereby helping improve survival.
This trial accrued 891 patients with stage III or IV (T2N2-
3M0 or T3-4, any N, M0) squamous cell carcinoma of the
oropharynx, hypopharynx, or larynx. Patients in the experi-
mental arm had signiﬁcantly higher rates of grade 3 and 4 skin
reactions (both inside and outside radiation volumes),
radiation mucositis, fatigue, anorexia, and hypokalemia upto 90 days from the start of therapy; however the difference
did not persist after 90 days. In the efﬁcacy analysis no signif-
icant differences were found in progression free survival (PFS),
overall survival (OS), loco regional failure (LRF), or distant
metastasis. The toxicity data of this study showed about a
ten percent increase in grade 3 and 4 dermatitis and mucositis.
The results also reported more frequent interruptions in radi-
ation therapy (26.9% vs. 15.1%, respectively). The probable
reason for no added beneﬁt with addition of Cetuximab with
radio chemotherapy may be due to similar mechanism of
radio-sensitization for both Cetuximab and cisplatin. The high
rate of toxicity burden and treatment interruptions also
appears to have contributed to suboptimal results. Also note
must be made that accelerated fractionation was used in this
trial in both arms which may have contributed to more acute
adverse reactions. Subset analysis revealed a better 3-year
probability of PFS and OS for patients with p16-positive
oropharyngeal carcinoma, compared with patients with p16-
negative oropharyngeal carcinoma.
Martins et al. conducted a phase II trial evaluating the ben-
eﬁt of addition of erlotinib to cisplatin and radiotherapy in
locally advanced squamous cell carcinoma of the head and
neck [14]. 204 patients were randomly assigned to two arms
containing radiotherapy with cisplatin with or without erloti-
nib. But the addition of erlotinib neither increased complete
response rate or progression-free survival compared to cis-
platin and radiotherapy alone.
Subsequently, other anti-EGFR agents were also evaluated
in various phase II trials. Basavaraj et al. in a phase II study
evaluated the beneﬁt of adding Nimotuzumab to chemoradia-
tion [15]. In this study which included 92 patients it was seen
that EGFR expression showed a signiﬁcant relationship to
patient survival in patients treated with Nimotuzumab and
chemoradiation (p= 0.02).
The CONCERT I trial randomized patients to receive radio
chemotherapy with or without Panitumumab, a fully human
monoclonal antibody that targets EGFR. This trial accrued
locally advanced squamous-cell carcinoma of the head and
neck (Stage III, IVa, or IVb, previously untreated) to receive
radio chemotherapy (three cycles of cisplatin 100 mg/m2) or
Panitumumab plus radio chemotherapy (three cycles of intra-
venous Panitumumab 9.0 mg/kg every 3 weeks plus cisplatin
75 mg/m2). Primary endpoint was local-regional control at
2 years. The trial reported local regional control of 68% in
the standard arm compared to 61% in the experimental arm.
The PFS and OS did not support the experimental arm [16].
Adverse events like grade 3 and 4 dysphagia (27% vs. 40%),
mucosal inﬂammation (24% vs. 55%), and dermatitis (13%
vs. 31%) were more common in the Panitumumab arm. Serious
adverse events were reported in 43% patients in the Panitu-
mumab plus chemo radio therapy group compared to 32% in
the radio chemotherapy only group. Use of suboptimal dose
of cisplatin (75 mg/m2) may have contributed to inferior results
in this trial. Point should be made that compromise in the total
chemotherapy dose may not be compensated by addition of
targeted therapy irrespective of the biomarker status.
Hence with the available data there is no beneﬁt in adding
targeted to concurrent chemo radiotherapy in locally advanced
carcinoma of head and neck. In addition it adds signiﬁcantly
to the toxicity. Hence, selective addition of anti EGFR therapy
to patients with EGFR over expression may be evaluated
further.
Table 1 Summary of various trials that have evaluated the role of targeted therapy in radical setting.
Study Type Trial Design Outcome Toxicity Comments
Magrini
n= 70
[17]
Phase II CTRT vs. BioRT
(cetuximab)
Loco regional control, patterns of failure,
and survivals were similar between the
treatment arms
GI toxicities more in CTRT arm
Cutaneous toxicity and the need for nutritional
support more in BioRT arm
RT discontinuation for more than
10 days more in BioRT ARM(13%
vs. 0%)
Sakashita
n= 33
[18]
Retrospective Cetuximab-based BioRT
vs. CTRT
– Higher incidence of GradeP 3 radiation
dermatitis in BioRT (43% vs. 3%)
Higher incidence of GradeP 3 mucositis/
stomatitis in BioRT (64.3% vs.41.4%)
Lower incidence of inability to feed orally in
BioRT (38.5% vs. 55.2%)
Strom
n= 279
[19]
Retrospective CTRT vs. BioRT
(cetuximab)
No diﬀerence in loco regional control,
distant metastasis rate, or overall survival
Levy
n= 124
[20]
CBRT after Taxane
based induction
chemotherapy
Radio dermatitis (97%)
Skin rash (65%)
Occurrence of rash – improved
3 year OS in patients
Petrelli
n= 1808
[10]
Meta-
analysis
CTRT vs. BioRT
(cetuximab)
CTRT signiﬁcantly improved
 2-year OS (RR = 0.66)
 2-year PFS (RR = 0.68)
Thomson
n= 27 [23]
Phase-I/II
trial
Cetuximab with hypo
fractionated RT
At a median follow-up of 47 months,
overall cause-speciﬁc survival 79%
Grade 3 acute toxicities
 Pain (81%)
 Oral mucositis (78%)
 Dysphagia (41%)
Used hypo fractionated IMRT,
62.5 Gy in 25 daily fractions
Shapiro
n= 360
[24]
Retrospective Cisplatin + RT
Cetuximab + RT
Carboplatin, 5FU+ RT
Cetuximab– inferior 4-year OS and loco
regional control
Late toxicity
5FU/carboplatin (25.0%) vs. Cisplatin (8.0%) vs.
Cetuximab (7.7%)
Cetuximab arm
 Patients with poor performance
status, older age
Egloﬀ
n= 60
[25]
Phase II RT+ Cetuximab
+ Cisplatin
2 year OS 66% GradeP 3 toxicities
 Mucositis (55%)
 Dysphagia (46%)
 Neutropenia (26%)
HPV(+) patients had signiﬁcantly
longer OS and PFS (p= 0.004 and
0.036)
Saigal
n= 16
[26]
Retrospective Deﬁnitive carboplatin
+ Cetuximab + RT
Three-year loco regional recurrence
28.3%
3 patients experienced a treatment delay and three
did not ﬁnish RT
Wanebo
n= 64
[27]
Phase II Cetuximab, Paclitaxel,
and Carboplatin used as
induction therapy and
concomitant with RT
OS 78% at 3 years
EFS 55% at 3 years
24.2% Grade III hematological toxicity
15.75 Grade III rash
21.4% Radiation dermatitis
Levy
n= 265
[21]
Retrospective Cisplatin-based CRT
Cetuximab-based BioRT
2-year LRC: 76% for CRT vs. 61% for
BioRT
2-year LRC: 81% for CRT vs. 68% for
BioRT
BioRT patients had more G3-4 skin complications
(p < 0.001) and CRT patients had higher rates of
feeding tube placement (p = 0.006) and G3-4
gastrointestinal toxicities (p < 0.001)
Patients receiving BioRT
 More pre-existing condi-
tionsSubgroup analyses showed
that T4 patients beneﬁted signif-
icantly from CRT (vs. BioRT)
in LRC
Ley
n= 47
[22]
Retrospective Cisplatin-based CRT
Cetuximab-based BioRT
3 year DSS 83% in the cisplatin group vs.
31% in the cetuximab group
51% requirement for PEG tube in BioRT group
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Anti EGFR therapy in the treatment of head and neck carcinoma 145A summary of various trials that have evaluated the role of
targeted therapy in radical setting in patients with locally
advanced head and neck cancer is given in Table 1 [10,17–28].
Targeted therapy with radical radiotherapy after induction
chemotherapy
In the recent years organ preservation approach has become
feasible without compromising on survival with the advent
of radio-chemotherapy as well as neoadjuvant chemotherapy
protocols. Neoadjuvant chemotherapy followed by radiation
or radio-chemotherapy protocols for laryngeal or hypopharyn-
geal primary received great momentum. However, chemother-
apy toxicity remains an important barrier to this. In this
context less toxic anti-EGFR monoclonal antibody Cetuximab
was evaluated in phase II trial for organ preservation in stage
III and IV laryngeal or hypo pharyngeal cancers [TREMPLIN
Trial] [29]. This phase II trial included 116 patients, TPF reg-
imen 3 cycles were used for induction chemotherapy and
patients with more than 50% response were randomized to
receive radio chemotherapy with cisplatin vs. radiotherapy
with Cetuximab. When data were analyzed there was no signif-
icant difference in larynx preservation at 3 months between the
two arms. There was also no signiﬁcant difference in overall
survival at 18 months between the two arms. There was no dif-
ference in grade 3 and 4 mucositis between the two arms, but
more grade 3 and 4 in-ﬁeld skin toxicity was observed in the
Cetuximab arm. Hematological toxicity and protocol modiﬁ-
cation due to toxicity was higher in cisplatin arm compared
to Cetuximab.
Though this trial showed no difference in outcomes in bio-
radiotherapy vs. chemo radiotherapy in organ preservation,
further phase III data may be required before routinely incor-
porating bioradiotherapy in organ preservation protocols.
However, one may argue that bio radiotherapy may be an
option in patients not suitable for chemotherapy without com-
promising the outcome.
Attempts have also been made to assess the feasibility of
adding Cetuximab with radiation after induction chemother-
apy for LAHNSCC. Ghi et al. randomly assigned 421 patients
to 421 patients with LASCCHN of the oral cavity, orophar-
ynx, hypopharynx, stage III-IV, ECOG PS 0-1 to one of four
treatment options: Arm A1: CRT (cisplatin/5ﬂuorouracil  2
concomitant to standard RT fractionation); Arm A2: CET/
RT; Arm B1: 3 cycles of TPF followed by the same CRT;
and Arm B2: 3 cycles of TPF followed by CET/RT [30]. The
authors reported radiological CR 43.5% in induction and
28% in concomitant arm (p= 0.002). Median PFS was
29.7 months in induction vs. 18.5 in concomitant arm with a
3-year PFS of 46.8% vs. 36.7% (HR: 0.73; 95%CI 0.57–
0.94; p= 0.015), respectively. Median OS was 53.7 months
in induction vs. 30.3 in concomitant arm with a 3-year OS of
57.6% vs. 45.7% (HR: 0.72; 95%CI 0.55–0.96; p= 0.025)
respectively. Compliance to concomitant treatments was not
affected by induction TPF. Italian INTERCEPTOR trial also
aimed to assess feasibility of adding Cetuximab with radiation
following induction chemotherapy. This randomized multicen-
ter phase III study comparing CTRT versus induction
chemotherapy followed by bioradiation (RT + Cetuximab).
The primary endpoint is overall Survival and secondary end
points are Response Rate (RR), Progression Free survival
Table 2 Summarizes different trials using Cetuximab in concurrent, induction setting for locally advanced HNSCC.
Author/year/Phase/N Study arm Results Adverse eﬀects
Magrini et al., 2015/Phase II/ 70 RT+ Cisplatin versus
RT+ Cetuximab
Locoregional control,
patterns of failure, and
survivals were similar
Serious adverse events higher in the
Cetuximab arm (19% v 3%, p= .044)
Argiris et al., 2010/Phase II/39 ICT (TPE)? RT+ Cetuximab 3-year PFS and OS- 70%
and 74%
Grade III/IV-neutropenic fever (10%),
grade 3 or 4 oral mucositis (54%) and
hypomagnesemia (39%)
Kies et al., 2010/Phase II/47 ICT (Paclitaxel + Carboplatin
+ Cetuximab)? RT/CTRT/
Surgery
3 year PFS, OS-87%,
91%
Grade III/IV-rash-45%, Neutropenia-
21%
Mesı´a et al., 2016/Phase II/50 ICT (C-TPF)? sequential
accelerated RT with concomitant
boost (69.9 Gy) + weekly cetuximab
median overall survival
(OS) was 40.7 months
2 year LRC-57%
Grade III/IV-neutropenia (24%),
neutropenic fever (24%), and diarrhea
(20%), Death 6%
Haddad et al., 2009/Phase I/30 ICT (C-TPF)? CTRT overall response rate of
100%
Grade III-Rash 3%
Pﬁster et al., 2006/Phase II/22 RT+ Cisplatin + Cetuxiamb 3 year PFS, OS, LRC-
56%, 76%, 71%
Grade III/IV-Rash 10%,
hypersensitivity-5%
RT, radiotherapy; ICT, induction chemotherapy; CTRT, chemoradiotherapy; OS, overall survival; PFS, progression free survival; LRC,
locoregional control.
146 R. Benson et al.(PFS) role of Biomolecular prognostic factors (EGFR, HPV)
and toxicities. Table 2 summarizes different trials using Cetux-
imab in concurrent or induction setting for locally advanced
HNSCC [32–37].
Targeted therapy and HPV
Radiation therapy oncology group 1016 is a Phase III non-
inferiority study that will evaluate whether the substitution
of cisplatin with Cetuximab in concurrent radio chemotherapy
regimens employing accelerated intensity modulated radiother-
apy (70 Gy/6 weeks) achieves similar survival with lower toxi-
city in these favorable patients. In this regard Siu et al.
published results of the ﬁrst phase III de-escalation trial 320
patients were randomly assigned to receive standard fraction-
ation radiation with concurrent cisplatin or accelerated frac-
tionated radiation with concurrent Panitumumab. With a
median follow-up of 46.4 months, PFS was not superior in
the cisplatin arm compared to Panitumumab arm. However,
the direct comparison is not possible as the trial did not have
a Panitumumab with standard fraction radiation arm [31].
Conclusion
The targeted agents in head and neck cancer appeared with
great enthusiasm to improve survival with or without limiting
the toxicity of the conventional cytotoxic agents. The current
evidence does not support replacement of cisplatin with tar-
geted therapy in concurrent setting in patients who can tolerate
cisplatin. It may be considered in patients with altered renal
parameters, hypersensitivity or intolerance to cisplatin. The
addition of targeted therapy in addition to chemotherapy in
the concurrent setting leads to a signiﬁcant increase in toxicity
without additional survival beneﬁt and thus cannot be recom-
mended. The question of using Cetuximab in patients with
good prognosis like those with HPV positivity needs to be fur-
ther addressed. The results of the radiation therapy oncology
group 1016 trial may be helpful in this regard.Disclosures
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